Global Breast Cancer Screening Market is projected to be more than US$ 20 Billion by the year 2022

Access Full Research: http://www.renub.com/breast-cancer-screening-mammography-mri-and-ultrasound-market-and-forecast-worldwide-63-p.php

Get 10% Free Customization in this Report.

Press Release - Breast Cancer Screening: Today's Obstacle and Tomorrow's promise
Breast cancer screening is conceded out to detect cancer in its premature stages and ensure timely treatment of the patients. A bunch of innovative medicines, as well as tests for the cancer patients with an extensive multiplicity of tumor types and based on capable new mechanisms of action, has enhanced the enthusiasm about prospects for major approaches in breast cancer treatment. The large number of new medicines at present are in scientific development or under dogmatic review recommends.
Mammogram, screening, MRI, Ultrasound do not prevent breast cancer but they are helpful in early detection of breast cancer. Renub Research predicts that by the year 2022, Breast Cancer Screening Market is projected to be more than US$ 20 Billion.

Types of Breast Cancer Screening Tests
Mammogram
Mammogram is an X-ray of the breast. It could be the best way to find breast cancer at early stages. The Mammogram could not prevent from cancer but it can save lives by discovering cancer at earliest. In most developed nations, the mammogram is integrated with government breast cancer screening program while in less developed nations; mammogram is on prospects to be adopted by the government.

MRI Screening Market
In a breast MRI screening Test the method comprises magnets and radio waves to take the pictures of the breast. It is used along with mammogram to screen women who are at high risk for breast cancer. Mainly the developed nations led the breast cancer MRI screening test as it is a very effective procedure. The nations like Germany, United States, and France held control over half of the market in 2016. The other nations who control the market in MRI screening test were Canada, Italy and United Kingdom.

Ultrasound Test
Ultrasound is an imaging test which delivers high- frequency sound waves through the breast and converts into images on viewing screen. In this, no radiation is involved. Screening test for breast cancer is not using Ultrasound on its own either it is used to complement other screening tests. Though, the use of ultrasound in screening is linked with a high rate of both positive and negative outcomes.

Breast Cancer Screening Market and Population: Survey
The United States is the largest market for breast cancer screening market. China and Germany are at number third and second spot competing for the maximum number of shares in the market. The United Kingdom is at number fourth spot followed by Italy for the market share in the breast cancer screening.

In terms of breast cancer screening population, the nations like the United States, the United Kingdom, China, Japan and Germany captures almost 60 percent share of the global breast cancer screening in the year 2016. In addition, the nations like Spain, Italy, France, India and South Korea are the other nations who contribute to the breast cancer screening population.

A look at Global spending on Cancer
Global spending on cancer medicines – including supportive care and therapeutic treatments, and measured at ex-manufacturer prices not reflecting off-invoice discounts, rebates and patient access schemes reached US$ 100 Billion, up from US$ 75 Billion five years earlier.
• Since 2011, In the main developed markets, a sharp growth in the volume of protected brands and considerable new product launches have been the main drivers of spending expansion, while the effects of patent expiries have moderated over the years.
• On a per capita basis, spending reached US$ 99 in 2014, up from US$ 71 in 2010 on therapeutic cancer medicines in the United States.
• Oncology drugs spending has risen marginally as a level of aggregate medication spending in the course of recent years in all regions, most strikingly in the EU5 nations where oncology now speaks to 14.7% of aggregate medication spending, up from 13.3% out of 2010, while the U.S. has seen oncology increment all the more humbly from 10.7% to 11.3% of aggregate medication spending over a similar period.
• Future spending on oncology medicines through 2018 are relied upon to be in the 6-8% territory, contrasted with 6.5% in the course of recent years as developing interest and new treatment choices are balanced to some degree by new rivalry from bio similar and small molecule generics following patent expiries.

Contact Us
Rajat Gupta
Sr. Marketing Manager
Email: info@renub.com
Phone: +1-678-302-0700
Web: www.renub.com

Renub Research is a leading Market Research and Information Analysis Company with centers at Noida India and Roswell USA. We have long-term experience especially in international Business-to-Business Researches, Surveys, Business and Consulting. Throughout the years we have acquired expertise in most market sectors, including Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others.

Our core team is comprised of an experienced people holding graduate, post graduate and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science and many more. Our research help make the business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis and forecasting that is essential in today’s ultra-competitive markets.

225 Kristie Ln, Roswell, GA 30076, United States

This release was published on openPR.